Maze Therapeutics, Inc. (MAZE)
NASDAQ: MAZE · Real-Time Price · USD
28.85
+0.99 (3.55%)
Oct 8, 2025, 2:07 PM EDT - Market open
Maze Therapeutics Revenue
Maze Therapeutics had revenue of $2.50M in the twelve months ending June 30, 2025, down -98.48% year-over-year. In the year 2024, Maze Therapeutics had annual revenue of $167.50M.
Revenue (ttm)
$2.50M
Revenue Growth
-98.48%
P/S Ratio
215.55
Revenue / Employee
$20,000
Employees
125
Market Cap
1.27B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 167.50M | - | - |
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionMAZE News
- 2 days ago - Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors - GlobeNewsWire
- 26 days ago - Maze Therapeutics, Inc. (MAZE) Discuses On MZE782 Phase 1 Healthy Volunteer Trial Results Call (Transcript) - Seeking Alpha
- 27 days ago - Maze Shares Jump As Investors Bet Big On Experimental Treatment's Potential - Benzinga
- 27 days ago - Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement - GlobeNewsWire
- 27 days ago - Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD) - GlobeNewsWire
- 5 weeks ago - Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer - GlobeNewsWire
- 6 weeks ago - National Advertising Division Refers Maze Therapeutics to Regulatory Authorities for Failure to Respond to Inquiry - GlobeNewsWire
- 2 months ago - Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights - GlobeNewsWire